CEL-SCI To Launch Phase 3 Confirmatory Study

CEL-SCI Corporation

CVM

0.00

Patient enrollment expected to commence at clinical centers in the U.S., Europe, Asia and later on in South America
The 212-patient confirmatory study is powered at approximately 97% to confirm a previously observed 0.34 hazard ratio, representing a 66% reduction in the risk of death
In the target population, Multikine followed by standard of care increased the 5-year survival rate to 73% versus 45% with standard of care alone
Pre-surgical tumor responses will be assessed and may serve as the basis for an early conditional or accelerated approval application with the FDA

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.